In this video, we will discuss the pathology of carcinoid tumors of lung

Film about treatment options for neuroendocrine lung tumors with dr. Wieneke Buikhuisen, oncologist and dr. Koen Hartemink, lung surgeon, The Netherlands Cancer Institute Antoni van Leeuwenhoek , Amsterdam

Triparna Sen, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, talks on an investigation into molecular drivers and therapeutic targets for neuroendocrine transformation in lung cancer. EGFR-mutant adenocarcinoma transforms into small cell lung cancer (SCLC) as a mechanism of resistance to tyrosine kinase inhibitors (TKIs). A mutliomic analysis was conducted on combined histology tumors, whereby the lung adenocarcinoma and SCLC components were in the same spatial region. Microdissection of samples were performed and analyzed via various platforms, including Whole Exome Sequencing (WES), bulk RNA-sequencing, methylation analysis and immunohistochemistry. Via WES, p53 and RB1 loss were found in almost all combined histology tumors. Via bulk RNA-Seq, NOTCH inhibition and upregulation of several PCR2 complexes and DNA damage response genes were shown to be predictors of transformation. Additionally, AKT inhibition demonstrated to be an effective therapeutic target in a mutant mouse model. Notably, the addition of osimertinib to AKT inhibition performed better in mouse models than either agent alone. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.

Hear Rachael speak about her difficult journey to diagnosis of neuroendocrine cancer, her treatment experience, and the effect of the diagnosis on her life.

©2022 Novartis AG

Andrew E. Hendifar, MD, and Eric Liu, MD, FACS, recognize current challenges surrounding the treatment of neuroendocrine tumors and suggest ways to address limitations and optimize care for patients.

Dr. Maggie Ryan, 2016 LungNET Conference, Jun 11 in Denver CO